Abstract
59 - Efficacy and safety of durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer: a single institution experience at University Hospital of North Midlands (UHNM) in the United Kingdom (UK)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
